Evaluating the safety of bevacizumab in non-squamous NSCLC patients -Observational study-

Evaluating the safety of bevacizumab in non-squamous NSCLC patients -Observational study- - Evaluating the safety of bevacizumab in non-squamous NSCLC patients -Observational study-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011917

Enrollment

120

Registered

2013-09-30

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-squamous non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histological or cytological diagnosis of non-squamous NSCLC (2)Provided written consent in person for participation in this study (3)Age 20 years or older (4)ECOG Performance Status (PS) 0 to 2 (5)Have measurable lesions according to the Response Evaluation Criteria in Solid Tumors ver1.1 (6)Have adequate function of major organs (bone marrow, liver, kidneys) defined as follows: Neutrophils>=1,500 /mm3 Platelets>=100,000 /mm3 Hemoglobin>8.0 g/dl AST and ALT<=100IU/l Serum creatinine<=1.5 mg/dl

Exclusion criteria

Exclusion criteria: (1)Received transfusion or G-CSF within 14 days prior to enrollment (2)Urine protein>=2+ (3)History of drug allergy (4)Active multiple cancers (5)Severe infection (6)High fever (7)Abnormal cardiac function (8)Severe pulmonary disease; Interstitial pneumonia, severe COPD, pulmonary thromboembolism (9)Need for drainage of pleural effusion, acsites or pericardial effusion (10)History of hematoemesis, ileus and gastroduodenal ulcer (11)symptomatic CNS metastases (12)CNS or Psychological disorders (13)Medically uncontrolled hypertension or diabetes mellitus (14)Nonhealing wound and surgery within 4 weeks before treatment (15)History of hemoptysis; one-half teaspoon of bright red blood per event (16)Therapeutic anticoagulation(full-dose therapeutic anticoagulation current and recent use of aspirin (>=325 mg/day) (17)severe bone marrow suppression (18)Pregnancy or lactation

Design outcomes

Secondary

Measure	Time frame
PFS:Progression Free Survival DCR:Disease Control Rate ORR:Overall Response Rate TTF:Time to treatment failure OS:Overall Survival Safety and efficacy in patients with brain metastases	—

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactMasahiro Kodani

Faculty of Medicine, Tottori University Division of Medical Oncology

kodani@med.tottori-u.ac.jp0859-38-6537

Outcome results